Search

Your search keyword '"Lunning, Matthew A."' showing total 750 results
Start Over Author "Lunning, Matthew A."
750 results on '"Lunning, Matthew A."'

51. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Author

Jacobson, Caron A., Locke, Frederick L., Ma, Long, Asubonteng, Julius, Hu, Zhen-Huan, Siddiqi, Tanya, Ahmed, Sairah, Ghobadi, Armin, Miklos, David Bernard, Lin, Yi, Perales, Miguel-Angel, Lunning, Matthew Alexander, Herr, Megan M., Hill, Brian T., Ganguly, Siddhartha, Dong, Hua, Nikiforow, Sarah, Hooper, Michele, Kawashima, Jun, Xu, Hairong, and Pasquini, Marcelo C.

Published
2022
Full Text
View/download PDF

55. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Hamadani, Mehdi, additional, Nachiappan, Muthiah, additional, Leslom, Salman, additional, Kahl, Brad S., additional, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian T., additional, Lunning, Matthew A., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Lossos, Izidore S., additional, Caimi, Paolo F., additional, Han, Sunwoo, additional, Yang, Fei, additional, Kuker, Russ A., additional, and Moskowitz, Craig H., additional

Published
2023
Full Text
View/download PDF

58. POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)

Author

Lunning, Matthew, primary, Deger, Kristen A., additional, Liu, Fei Fei, additional, Elsada, Ahmed, additional, Klijn, Sven L., additional, Litkiewicz, Michal, additional, Franco-Villalobos, Conrado, additional, and Sorensen, Sonja V., additional

Published
2023
Full Text
View/download PDF

59. MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

Author

Palomba, M. Lia, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V., additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Dehner, Christine, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

60. CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)

Author

Lunning, Matthew, primary, Deger, Kristen A., additional, Liu, Fei Fei, additional, Elsada, Ahmed, additional, Klijn, Sven L., additional, Litkiewicz, Michal, additional, Franco-Villalobos, Conrado, additional, and Sorensen, Sonja V., additional

Published
2023
Full Text
View/download PDF

61. POSTER: MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

Author

Palomba, M. Lia, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V., additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Dehner, Christine, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

63. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Author

García-Ramírez, Idoia, Tadros, Saber, González-Herrero, Inés, Martín-Lorenzo, Alberto, Rodríguez-Hernández, Guillermo, Moore, Dalia, Ruiz-Roca, Lucía, Blanco, Oscar, Alonso-López, Diego, Rivas, Javier De Las, Hartert, Keenan, Duval, Romain, Klinkebiel, David, Bast, Martin, Vose, Julie, Lunning, Matthew, Fu, Kai, Greiner, Timothy, Rodrigues-Lima, Fernando, Jiménez, Rafael, Criado, Francisco Javier García, Cenador, María Begoña García, Brindle, Paul, Vicente-Dueñas, Carolina, Alizadeh, Ash, Sánchez-García, Isidro, and Green, Michael R.

Published
2017
Full Text
View/download PDF

65. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

68. P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

Author

Shah, Nirav, primary, Maziarz, Richard, additional, Jacobson, Caron, additional, Isufi, Iris, additional, Ghosh, Monalisa, additional, Ulrickson, Matthew, additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Nancy, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Madhavi, additional, Coleman, Kimberly, additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remigiusz, additional, and Miklos, David, additional

Published
2023
Full Text
View/download PDF

69. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma:primary analysis of the phase 3 TRANSFORM study

Author

Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali, Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali

Abstract

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor–positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.

Published
2023

70. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma

Author

Stuver, Robert, primary, Horwitz, Steven M., additional, Advani, Ranjana H., additional, Vose, Julie M., additional, Lee, Hun Ju, additional, Mehta‐Shah, Neha, additional, Zain, Jasmine M., additional, Haverkos, Bradley, additional, Lechowicz, Mary Jo, additional, Moskowitz, Alison J., additional, Pham, Luu Q., additional, Leyden, Elizabeth, additional, Ansell, Stephen M., additional, and Lunning, Matthew A., additional

Published
2023
Full Text
View/download PDF

71. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐ H odgkin lymphoma: A phase I/ II study

Author

Vose, Julie M., primary, Ganguly, Siddhartha, additional, Bierman, Philip J., additional, Bociek, R. Gregory, additional, Lunning, Matthew, additional, Lyden, Liz, additional, Meza, Jane L., additional, Caimi, Paolo F., additional, and Armitage, James O., additional

Published
2023
Full Text
View/download PDF

75. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

Author

Shah, Nirav N., primary, Maziarz, Richard T, additional, Jacobson, Caron A., additional, Ghosh, Monalisa, additional, Isufi, Iris, additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Dr. Nancy Maureen, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Mrs. Madhavi, additional, Coleman, Kimberly C., additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remi, additional, and Miklos, David B., additional

Published
2023
Full Text
View/download PDF

76. Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Author

Abramson, Jeremy S., primary, Solomon, Scott R., additional, Arnason, Jon, additional, Johnston, Patrick B., additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew, additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Stepan, Lara, additional, Ogasawara, Ken, additional, and Kamdar, Manali, additional

Published
2023
Full Text
View/download PDF

78. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Abstract

Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.

Published
2024
Full Text
View/download PDF

79. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Author

Lunning, Matthew A., primary, Wang, Hai-Lin, additional, Hu, Zhen-Huan, additional, Locke, Frederick L., additional, Siddiqi, Tanya, additional, Jacobson, Caron A., additional, Ahmed, Sairah, additional, Miklos, David B., additional, Lin, Yi, additional, Hill, Brian T., additional, Ghobadi, Armin, additional, Neelapu, Sattva S., additional, Westin, Jason, additional, Miao, Harry, additional, Shahani, Shilpa, additional, Patel, Anik R., additional, Spooner, Clare, additional, Fu, Christine, additional, Xu, Hairong, additional, and Pasquini, Marcelo C, additional

Published
2022
Full Text
View/download PDF

80. Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Author

Abramson, Jeremy S., primary, Solomon, Scott R., additional, Arnason, Jon E., additional, Johnston, Patrick B., additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew A., additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, and Kamdar, Manali, additional

Published
2022
Full Text
View/download PDF

81. Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Author

Abramson, Jeremy S., primary, Kamdar, Manali, additional, Liu, Fei Fei, additional, Crotta, Alessandro, additional, Previtali, Alessandro, additional, Klijn, Sven L., additional, Wang, Pearl, additional, Situ, Aaron, additional, Zhang, Yixie, additional, Bonner, Ashley, additional, and Lunning, Matthew A., additional

Published
2022
Full Text
View/download PDF

82. Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Author

Ciuro, Jordan, primary, Henry, Elizabeth, additional, Housri, Nadine, additional, Banerjee, Rahul, additional, Brem, Elizabeth A, additional, Brooks, Taylor, additional, Derman, Ben A., additional, Hill, Brian T., additional, Hofmeister, Craig C, additional, Lunning, Matthew A., additional, Matasar, Matthew J., additional, Phillips, Tycel J., additional, Rutherford, Sarah C., additional, Zanwar, Saurabh, additional, and Lee, Lauren E, additional

Published
2022
Full Text
View/download PDF

83. Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Author

Alderuccio, Juan Pablo, primary, Kuker, Russ A, additional, Reis, Isildinha M, additional, Nachiappan, Muthiah, additional, Kahl, Brad S., additional, Hamadani, Mehdi, additional, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian T., additional, Lunning, Matthew A., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Yu, Eric, additional, Caimi, Paolo F, additional, Kwon, Deukwoo, additional, Lossos, Izidore S., additional, Yang, Fei, additional, and Moskowitz, Craig H., additional

Published
2022
Full Text
View/download PDF

84. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Author

Khurana, Arushi, primary, Bailey, Megumi, additional, Iqbal, Madiha, additional, Bansal, Radhika, additional, Lee, Catherine J., additional, Hunter, Bradley, additional, Lunning, Matthew A., additional, Jaglowski, Samantha, additional, Jain, Michael D., additional, Dahiya, Saurabh, additional, Bachanova, Veronika, additional, Farooq, Umar, additional, Ahmed, Sairah, additional, Hill, Brian T., additional, Munoz, Javier L., additional, Patel, Krish, additional, Oluwole, Olalekan O., additional, and Lin, Yi, additional

Published
2022
Full Text
View/download PDF

85. Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Author

Locke, Frederick L., primary, Hu, Zhen-Huan, additional, Siddiqi, Tanya, additional, Jacobson, Caron A., additional, Nikiforow, Sarah, additional, Ahmed, Sairah, additional, Miklos, David B., additional, Lin, Yi, additional, Lunning, Matthew A., additional, Hill, Brian T., additional, Ghobadi, Armin, additional, Miao, Harry, additional, Shahani, Shilpa, additional, Spooner, Clare, additional, Fu, Christine, additional, Patel, Anik R., additional, Xu, Hairong, additional, and Pasquini, Marcelo C, additional

Published
2022
Full Text
View/download PDF

86. CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL

Author

Iqbal, Madiha, primary, Tun, Han, additional, Joffe, Erel, additional, Grommes, Christian, additional, Nowakowski, Grzegorz, additional, Lunning, Matthew, additional, Ramchandren, Radhakrishnan, additional, Li, Chia-Cheng, additional, Zhao, Wanying, additional, Martinez, Elizabeth, additional, von Roemeling, Reinhard, additional, Earhart, Robert, additional, McMahon, Meaghan, additional, Isufi, Iris, additional, Leslie, Lori, additional, and Rosenthal, Allison, additional

Published
2022
Full Text
View/download PDF

89. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study.

Author

Vose, Julie M., Ganguly, Siddhartha, Bierman, Philip J., Bociek, R. Gregory, Lunning, Matthew, Lyden, Liz, Meza, Jane L., Caimi, Paolo F., and Armitage, James O.

Subjects
HEMATOPOIETIC stem cell transplantation, NON-Hodgkin's lymphoma, DIFFUSE large B-cell lymphomas, LENALIDOMIDE, MANTLE cell lymphoma
Abstract

Summary: Improved maintenance treatments are needed for patients with relapsed/refractory aggressive lymphomas after autologous haematopoietic stem cell transplantation (ASCT). Several studies with lenalidomide have been found to have activity in the treatment of relapsed/refractory aggressive lymphomas. In the present phase I/II, single‐arm, open‐label study, 59 patients with high‐risk relapsed non‐Hodgkin lymphoma received pretransplant BEAM chemotherapy and ASCT followed by 12 months of maintenance lenalidomide once daily on Days 1–21 (28‐day cycles) beginning at post‐transplantation Day 100. The most common histologies were mantle cell lymphoma (56%) and diffuse large B‐cell lymphoma (24%). The maximum tolerated dose in the dose‐finding part of the study was 15 mg, but cytopenias led to the subsequent adoption of a 10 mg dose in the final study. Sixteen patients (27%) completed 12 cycles of lenalidomide maintenance. The most common reason for discontinuation was adverse events (31%). These were primarily haematologic, and 56% of patients experienced Grade 3–4 events. Two‐year PFS rates (95% CIs) were 70% (56%–80%), 45% (19%–68%) and 81% (66%–90%); 2‐year OS rates (95% CIs) were 91% (80%–96%), 93% (61%–99%) and 90% (76%–96%) in all patients, patients completing and patients not completing 12‐month maintenance respectively. These results do not support the use of lenalidomide maintenance in this setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

92. Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.

Author

Joffe, Erel, primary, Nowakowski, Grzegorz S., additional, Tun, Han W., additional, Rosenthal, Allison Claire, additional, Lunning, Matthew Alexander, additional, Ramchandren, Radhakrishnan, additional, Li, Chia-Cheng, additional, Zhou, Li, additional, Martinez, Elizabeth, additional, Von Roemeling, Reinhard W., additional, Earhart, Robert H., additional, McMahon, Meaghan, additional, Isufi, Iris, additional, and Leslie, Lori Ann, additional

Published
2022
Full Text
View/download PDF

93. Experience of using venetoclax in relapsed T- cell lymphoma.

Author

Zain, Jasmine, Lunning, Matthew, and Rosen, Steven

Subjects
*CUTANEOUS T-cell lymphoma, *TUMOR lysis syndrome, *T-cell lymphoma, *MYCOSIS fungoides, *STEM cell transplantation, *CELL transformation
Abstract

This document discusses the use of the drug venetoclax in the treatment of relapsed peripheral T-cell lymphoma (PTCL). The study aimed to assess the overall response rate of venetoclax as a single agent in PTCL patients. However, the study had to be amended due to rapid disease progression in some patients, and ultimately, the study was closed without completing the safety lead-in. Although the study showed the futility of using venetoclax as a single agent, the lack of unacceptable toxicity suggests the possibility of studying venetoclax in combination with other drugs. [Extracted from the article]

Published
2024
Full Text
View/download PDF

94. Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Author

Abramson, Jeremy S., primary, Palomba, M. Lia, additional, Gordon, Leo I., additional, Lunning, Matthew, additional, Wang, Michael, additional, Arnason, Jon E., additional, Purev, Enkhtsetseg, additional, Maloney, David G., additional, Andreadis, Charalambos, additional, Sehgal, Alison R., additional, Solomon, Scott R., additional, Ghosh, Nilanjan, additional, Kostic, Ana, additional, Kim, Yeonhee, additional, Ogasawara, Ken, additional, Dehner, Christine, additional, and Siddiqi, Tanya, additional

Published
2022
Full Text
View/download PDF

95. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Author

Kamdar, Manali, primary, Solomon, Scott R., additional, Arnason, Jon E., additional, Johnston, Patrick B, additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco J, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew, additional, Maloney, David G., additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Stepan, Lara, additional, Ogasawara, Ken, additional, Mack, Timothy, additional, and Abramson, Jeremy S., additional

Published
2022
Full Text
View/download PDF

96. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Author

Spiegel, Jay, primary, Dahiya, Saurabh, additional, Nastoupil, Loretta J., additional, Tamaresis, John, additional, Ghobadi, Armin, additional, Lin, Yi, additional, Lekakis, Lazaros J., additional, Reagan, Patrick M., additional, Oluwole, Olalekan O., additional, McGuirk, Joseph P., additional, Deol, Abhinav, additional, Sehgal, Alison R., additional, Goy, Andre H., additional, Hill, Brian T., additional, Andreadis, Charalambos, additional, Muñoz, Javier, additional, Ullrickson, Matthew, additional, Westin, Jason R., additional, Chavez, Julio C., additional, Jacobs, Miriam T, additional, Bennani, N. Nora, additional, Rapoport, Aaron P., additional, Vose, Julie M., additional, Miklos, David B., additional, Neelapu, Sattva S., additional, Locke, Frederick L., additional, Lunning, Matthew Alexander, additional, and Jain, Michael D, additional

Published
2022
Full Text
View/download PDF

98. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Author

Spiegel, Jay Y., Dahiya, Saurabh, Jain, Michael D., Tamaresis, John, Nastoupil, Loretta J., Jacobs, Miriam T., Ghobadi, Armin, Lin, Yi, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Goy, Andre, Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Bennani, N. Nora, Vose, Julie M., Dorritie, Kathleen A., Neelapu, Sattva S., Locke, Frederick L., Rapoport, Aaron P., Hill, Brian T., and Miklos, David B.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results